Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

GLGe LiuQWQian WangQYQingsong Yin

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows that a 14-day blinatumomab regimen improves treatment outcomes in B-ALL, suggesting its role in inducing remission for MRD-negative patients.

Key Points

  • This research aims to evaluate the efficacy of a 14-day blinatumomab regimen in treating newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
  • Conducted a retrospective study involving B-ALL patients from two centers between January 2022 and May 2025
  • Analyzed patients receiving blinatumomab for induction or MRD-negative consolidation
  • Monitored T cell dynamics and treatment responses across Ph-positive and Ph-negative cohorts
  • Complete remission rate (CRc) of 100% in Ph+ patients with blinatumomab plus TKI during induction
  • CRc of 86.5% and 87.5% MRD negativity in Ph- patients receiving the treatment
  • After 14-day regimen, observed increased CD8+ T cell frequencies, correlating with treatment response and predicting outcomes.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d273https://doi.org/10.1182/blood-2025-3336
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of short-course versus standard-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia2025 · 1 citations
  2. 2Infusion of 14 days Blinatumomab in Combination with Chemotherapy for 46-day MRD+ Pediatric B-ALL Patients in Intermediate/High-Risk Group Results in MRD Conversion and BiTE Induced Immune Response to Malignant Cells2024
  3. 3Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol2024
  4. 4Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL2024 · 13 citations
  5. 5Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity2025